Impact PAMA Cuts – Infectious Disease Specialists
On January 1, 2019, outpatient clinical laboratory tests will receive the second of three 10% reimbursement cuts. These rates do not reflect market-based payments as intended by Congress under the Protecting Access to Medicare Act (PAMA).
IDSA, COLA, and other organizations remain concerned that the myriad issues with PAMA implementation have led to inappropriate new reimbursement rates for many tests. We are working to advocate for a reimbursement system that promotes innovative diagnostics and improves patient access to care, and we need your help to provide on-the-ground perspectives about the importance of near patient testing in the diagnosis and treatment of infectious disease.
Please complete this brief survey to share the impacts of declining reimbursement on laboratory operations and patient care. Email questions or additional comments to email@example.com. Thank you for your help in protecting patient access to diagnostic testing!